Page Six: Brianna LaPaglia vs. Celebrity GLP-1 Use, a stark split

In the latest page six-focused spotlight on Brianna “Chickenfry” LaPaglia, the influencer delivers a blunt warning about Ozempic use by people who “do not need” it, while other public figures in the same discussion have spoken openly about using GLP-1 medications for weight loss. Put side by side, the question becomes whether this is fundamentally a disagreement about the drug itself, or about who should be using it and why.

Brianna LaPaglia’s TikTok message frames Ozempic as a needless risk

LaPaglia, 26, laid out her view in a Tuesday TikTok video, introducing it as “No tea, no shade, no hate, just some field research. ” She said, “Every single bitch I know is on Ozempic. People that do not need Ozempic, ” and then drew a comparison to herself: “It’s like if I did Ozempic. Could I lose a couple? Surely. Do I need Ozempic? No!”

From there, she moved from observation to warning. LaPaglia delivered an urgent line aimed at people taking the drug “without cause”: “You’re gonna die. You’re all gonna die. ” Her remarks, as presented in the context, do not include a medical case-by-case standard; instead, they hinge on the idea that usage by people who do not need the drug is inherently dangerous.

The context also anchors her view in her own history with food and health. On the “Real Pod” podcast in February, she described an “anxiety-induced eating disorder, ” saying she was “always nauseous, ” and that “Anytime I ate something, I would throw up. ” She said she would “avoid food at all costs” because eating made her feel sick, and linked that pattern to anxiety-driven nausea.

LaPaglia also said she hit “rock bottom” in 2023, when she was at her lowest weight to date, and described her family’s reaction when she went home. She recalled being anemic, having bruises “all over” her, and later recognizing in the mirror that she looked “so unhealthy. ” After gaining 25 pounds back, she said she was at what she considered a “healthy weight, ” adding that it took “four or five months” to get back to a healthier weight and mindset.

Ozempic, Mounjaro, and the contrasting tone from Amanda Bynes and Vanessa Williams

LaPaglia’s warning sits alongside a different kind of public conversation: celebrities discussing GLP-1 drugs as tools they have chosen to use. The context states that Ozempic is a GLP-1 injection used to treat Type 2 diabetes, and that it is widely prescribed for weight loss. It also notes that similar drugs include Mounjaro, Zepbound, and Wegovy.

Within that landscape, two examples in the provided material illustrate a sharply different tone from LaPaglia’s. Amanda Bynes revealed last December that she had lost 28 pounds on Ozempic. Vanessa Williams told Hello! magazine in January that she has been combating menopausal weight gain with Mounjaro for the past two years, calling it “a game changer. ” The context identifies Williams as 62, and includes her explanation of motivation: “When I turned 60, I was like: ‘I want to be here for a long time, and I want to look my best. So what am I going to do?’”

Notably, these celebrity comments, as presented, emphasize outcomes and personal goals rather than warnings. They do not address the question LaPaglia centers: whether a user “needs” a GLP-1 drug, or what happens when it is used “without cause. ” The result is less a disagreement about the existence of risk and more a mismatch in what each speaker chooses to foreground.

page six comparison: a warning about “not needed” use versus a “game changer” narrative

Placed next to each other, LaPaglia’s remarks and the celebrity testimonials outline two competing frameworks for discussing GLP-1 drugs. LaPaglia’s framework is caution-first and eligibility-driven: she repeatedly stresses “People that do not need Ozempic, ” and uses her own hypothetical (“if I did Ozempic”) to argue that possibility of losing weight is not the same as necessity. By contrast, the public comments from Bynes and Williams are results-first and goal-driven: weight loss, menopausal weight gain, and the phrase “game changer. ”

There is also a concrete, shared factual bridge between the two sides: the context explicitly names potential harms when a GLP-1 is used when “not needed, ” including gallbladder and kidney problems, and it also mentions the potential for nutrient deficiencies. That means LaPaglia’s caution is not presented in a vacuum; the same material that includes celebrity endorsements also includes a list of serious side effects tied to unnecessary use.

Analysis: The divergence suggests that the public debate is being shaped less by a single set of agreed talking points and more by who is speaking and what they are disclosing. LaPaglia ties her stance to a personal history of disordered eating and a return to what she calls a “healthy weight, ” which can make a warning about quick weight-loss fixes feel more central. The celebrity examples included here focus on individual results and motivations, which can make the medications appear straightforwardly beneficial.

The finding from this comparison is clear: within the same slice of conversation, GLP-1 drugs are being framed in two incompatible ways—either as a high-stakes risk when used by people who “do not need” them, or as a practical tool that delivers weight-related results. The next confirmed data point that tests which framing dominates is the continued public sharing of personal GLP-1 outcomes like Bynes’ 28-pound loss and Williams’ two-year experience; if those disclosures keep centering benefits while warnings keep centering eligibility and side effects, the comparison suggests the debate will remain split over “need” versus “results, ” not simply over the drug’s existence.